全文获取类型
收费全文 | 4042篇 |
免费 | 260篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 59篇 |
儿科学 | 307篇 |
妇产科学 | 42篇 |
基础医学 | 482篇 |
口腔科学 | 104篇 |
临床医学 | 305篇 |
内科学 | 801篇 |
皮肤病学 | 146篇 |
神经病学 | 182篇 |
特种医学 | 315篇 |
外科学 | 549篇 |
综合类 | 125篇 |
预防医学 | 184篇 |
眼科学 | 132篇 |
药学 | 316篇 |
1篇 | |
中国医学 | 12篇 |
肿瘤学 | 263篇 |
出版年
2023年 | 26篇 |
2021年 | 94篇 |
2020年 | 57篇 |
2019年 | 64篇 |
2018年 | 100篇 |
2017年 | 60篇 |
2016年 | 70篇 |
2015年 | 82篇 |
2014年 | 118篇 |
2013年 | 146篇 |
2012年 | 224篇 |
2011年 | 222篇 |
2010年 | 156篇 |
2009年 | 123篇 |
2008年 | 153篇 |
2007年 | 162篇 |
2006年 | 153篇 |
2005年 | 139篇 |
2004年 | 122篇 |
2003年 | 109篇 |
2002年 | 94篇 |
2001年 | 90篇 |
2000年 | 58篇 |
1999年 | 89篇 |
1998年 | 101篇 |
1997年 | 96篇 |
1996年 | 75篇 |
1995年 | 75篇 |
1994年 | 53篇 |
1993年 | 66篇 |
1992年 | 86篇 |
1991年 | 79篇 |
1990年 | 61篇 |
1989年 | 96篇 |
1988年 | 79篇 |
1987年 | 63篇 |
1986年 | 70篇 |
1985年 | 56篇 |
1984年 | 43篇 |
1983年 | 33篇 |
1982年 | 33篇 |
1981年 | 32篇 |
1980年 | 29篇 |
1979年 | 36篇 |
1978年 | 26篇 |
1977年 | 31篇 |
1976年 | 43篇 |
1975年 | 29篇 |
1970年 | 28篇 |
1969年 | 27篇 |
排序方式: 共有4325条查询结果,搜索用时 569 毫秒
1.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
2.
3.
Prahlad V. Raninga Andy C. Lee Debottam Sinha Yu-Yin Shih Deepak Mittal Ashwini Makhale Amanda L. Bain Devathri Nanayakarra Kathryn F. Tonissen Murugan Kalimutho Kum Kum Khanna 《International journal of cancer. Journal international du cancer》2020,146(1):123-136
Triple-negative breast cancer (TNBCs) is a very aggressive and lethal form of breast cancer with no effective targeted therapy. Neoadjuvant chemotherapies and radiotherapy remains a mainstay of treatment with only 25–30% of TNBC patients responding. Thus, there is an unmet clinical need to develop novel therapeutic strategies for TNBCs. TNBC cells have increased intracellular oxidative stress and suppressed glutathione, a major antioxidant system, but still, are protected against higher oxidative stress. We screened a panel of antioxidant genes using the TCGA and METABRIC databases and found that expression of the thioredoxin pathway genes is significantly upregulated in TNBC patients compared to non-TNBC patients and is correlated with adverse survival outcomes. Treatment with auranofin (AF), an FDA-approved thioredoxin reductase inhibitor caused specific cell death and impaired the growth of TNBC cells grown as spheroids. Furthermore, AF treatment exerted a significant in vivo antitumor activity in multiple TNBC models including the syngeneic 4T1.2 model, MDA-MB-231 xenograft and patient-derived tumor xenograft by inhibiting thioredoxin redox activity. We, for the first time, showed that AF increased CD8+Ve T-cell tumor infiltration in vivo and upregulated immune checkpoint PD-L1 expression in an ERK1/2-MYC-dependent manner. Moreover, combination of AF with anti-PD-L1 antibody synergistically impaired the growth of 4T1.2 primary tumors. Our data provide a novel therapeutic strategy using AF in combination with anti-PD-L1 antibody that warrants further clinical investigation for TNBC patients. 相似文献
4.
Y K Khanna A Khanna R R Heda G Mathur R N Jhanji 《Journal of the Indian Medical Association》1991,89(2):35-38
Forty-nine cases of gastroduodenal perforation were subjected to new air insufflation test. The clinical and radiological criteria of air insufflation test were applied to every patient of this study. Forty-seven cases (95.9%) were positive to the new test whereas 2 negative cases turned out to be old sealing perforation. The new test is highly useful in preoperative detection of site of perforation in perforative peritonitis. 相似文献
5.
6.
7.
8.
Pyomyositis: characteristics at CT and MR imaging 总被引:9,自引:0,他引:9
9.
AJ Larner MRCP 《International journal of clinical practice》1994,48(5):272-274
SUMMARY A case is reported of pseudohyperphosphataemia in association with a monoclonal gammopathy of undetermined significance. 相似文献
10.
Three patients with interstitial cystitis diagnosed on the basis of clinical symptoms, classic endoscopic findings, and a typical histologic picture were treated with intravesical doxorubicin. All 3 patients showed remarkable improvement, as manifested by complete clearance of irritative bladder symptoms and healing of ulceration. Doxorubicin therefore may be the breakthrough drug for interstitial cystitis. 相似文献